Correction {#Sec1}
==========

After publication of the original article \[[@CR1]\] the authors found that Table 2 had been formatted incorrectly, meaning that some rows in the Table did not display the correct information.

An updated version of Table [2](#Tab1){ref-type="table"} is included with this Correction.Table 2Used cognitive tests, questionnaires and biological tests*MoCA* Montreal Cognitive Assessment, *WAIS* Wechsler Adult Intelligence Scale, *VOSP* Visual Object and Space Perception Battery, *fNART* French National Adult Reading Test, *ISI* Insomnia Severity Index, *VAS* Visual Analog Scale, *ADL* Activities of Daily Living, *IADL* Instrumental Activities of Daily Living, *MNA* Mini-Nutritional Assessment^a^Cognitive assessment will be performed by neuropsychologists^b^For group of interest patients: before the start of the treatment or within 15 days after the start of treatment by abiraterone acetate or enzalutamide^c^Had to be ≤3 on the 0--10 pain VAS scale to meet with inclusion pain criteria^d^Geriatric assessment will be performed by a study nurse specialized in geriatric^e^Adherence evaluation will be performed only in group of interest patients^f^At each time: CBC, platelets, albumin, CRP, prealbumin, iron, ferritin, transferrin, creatinin, sodium, potassium, ALT, AST, GGT, ALP, total bilirubin, TSH, T4, testosterone. At inclusion only: cortisol (at 8 h AM, fasting)^g^1 EDTA (5 ml), 1 dry tube with gel (5 ml) and 1 dry tube without gel (5 ml)

The original article has also been updated.

The online version of the original article can be found under 10.1186/s12885-017-3764-9
